Inogen Recognized as one of the Fastest Growing Companies in North America according to Deloitte’s 2017 Technology Fast 500...
November 09 2017 - 8:00AM
Business Wire
Achieved 169% Revenue Growth between 2013 and
2016
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced it was included on Deloitte’s Technology
Fast 500™, a ranking of the 500 fastest growing technology, media,
telecommunications, life sciences and energy tech companies in
North America. This is the fourth consecutive year that Inogen has
been named to the list. Inogen grew annual revenues from $75.4M to
$202.8M, or 169%, between 2013 and 2016.
Inogen’s President and CEO, Scott Wilkinson, attributes the
revenue growth to increased demand for the company’s innovative
products and its continued leadership in portable oxygen therapy
solutions. “It is truly an honor to be named to Deloitte’s
Technology Fast 500™ for the fourth straight time. This is evidence
of the growth in awareness of our portable oxygen therapy solutions
and an increase in the adoption of portable concentrators in the
oxygen market. The increase in revenues in our consumer and
business sales channels is a direct result of these factors. The
knowledge that there are millions of patients worldwide whose lives
can be improved through use of our products gives us bright hope
for the continued success of Inogen,” said Wilkinson.
About Deloitte’s 2017 Technology Fast 500™Deloitte’s
Technology Fast 500 provides a ranking of the fastest growing
technology, media, telecommunications, life sciences and energy
tech companies — both public and private — in North America.
Technology Fast 500 award winners are selected based on percentage
fiscal year revenue growth from 2013 to 2016.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD, and current-year
operating revenues of at least $5 million USD. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
As used in this document, “Deloitte” refers to one or more of
Deloitte Touche Tohmatsu Limited, a UK private company limited by
guarantee (“DTTL”), its network of member firms, and their related
entities. DTTL and each of its member firms are legally separate
and independent entities. DTTL (also referred to as “Deloitte
Global”) does not provide services to clients. In the United
States, Deloitte refers to one or more of the US member firms of
DTTL, their related entities that operate using the “Deloitte” name
in the United States and their respective affiliates. Certain
services may not be available to attest clients under the rules and
regulations of public accounting. Please see www.deloitte.com/about
to learn more about our global network of member firms.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
Use of Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements concerning awareness of Inogen’s products and the effect
of such awareness on future financial performance or trends and
growth opportunities affecting Inogen. Forward-looking statements
are subject to numerous risks and uncertainties that could cause
actual results to differ materially from currently anticipated
results, including, but not limited to, risks that Inogen will not
realize anticipated revenue and that future results could be
materially different from any future results expressed or implied
by these forward-looking statements. In addition, Inogen's business
is subject to numerous additional risks and uncertainties,
including, among others, risks relating to market acceptance of its
products; competition; its sales, marketing and distribution
capabilities; its planned sales, marketing, and research and
development activities; interruptions or delays in the supply of
components or materials for, or manufacturing of, its products;
seasonal variations; unanticipated increases in costs or expenses;
and risks associated with international operations. Information on
these and additional risks, uncertainties, and other information
affecting Inogen's business and operating results are contained in
Inogen's Annual Report on Form 10-K for the year ended December 31,
2016 and in Inogen's subsequent reports on Form 10-Q and Form 8-K,
including Inogen’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2017. These forward-looking statements speak
only as of the date hereof. Inogen disclaims any obligation to
update these forward-looking statements except as may be required
by law.
About InogenInogen is innovation in oxygen therapy. We
are a medical technology company that develops, manufactures and
markets innovative oxygen concentrators used to deliver
supplemental long-term oxygen therapy to patients suffering from
chronic respiratory conditions. For more information, please visit
www.inogen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171109005189/en/
InogenInvestor Relations Contact:Matt Bacso,
CFAmbacso@inogen.netorMedia Contact:Byron Myers, 805-562-0503
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024